Podcasts about biodesign institute

  AZ Bio Week & Life Sciences Innovation w/ Joan Koerber-Walker - AZ TRT S06 EP19 (281) 10-12-2025   Things We Learned This Week AZ Bio mission to improve life and bioscience, & make AZ a Top Ten Bioscience state AZ Bio Week 2025 - Oct. - 5 Days Talks, Events & Awards AZ Advances - nonprofit donation to biotech startups Aqualung Therapeutics is treating inflammation in the lungs, get people off ventilators & save lives Calviri is working on a Vaccine to PREVENT Cancer, currently largest animal clinical trial Anuncia Medical has a Re-Flow product to help drain fluid from the brain, treats Hydrocephalus     Guest: Joan Koerber-Walker President and CEO, AZBio - Arizona Bioindustry Association, Inc. Chairman, Opportunity Through Entrepreneurship Foundation   LKIN: https://www.linkedin.com/in/joankoerberwalker  www.azbio.org Bio: As President and CEO of AZBio, Joan Koerber-Walker works on behalf of the Arizona Bioscience and Medical Technology Industry to support the growth of the industry, its members and our community on the local and national level. Ms. Koerber-Walker is also a life science investor and has served on the boards of numerous for-profit and non-profit organizations. In the life science industry, Ms. Koerber-Walker serves as as Arizona's representative to the State Medical Technology Alliance (SMTA), a consortium of state and regional trade associations representing their local medical technology companies which she chaired in 2015 and  represents Arizona as a member of the Council of State Bioscience Associations (CSBA) and the Coalition of State Bioscience Institutes (CSBI). Active in the entrepreneurial and investment communities, she also serves as Chairman of the Board of the Opportunity Through Entrepreneurship Foundation which provides entrepreneurial education, mentoring and support to at-risk members of the community, on the Board of Advisors to CellTrust, Inc. which provides secure communication technology to the healthcare industry, and as Chairman of CorePurpose, Inc. which she founded in 2002. Ms. Koerber-Walker has been recognized as Executive of the Year by the Arizona Society of Association Executives, as a “Most Admired Leader” by the Phoenix Business Journal (2015),  in the pages of AZ Business Leaders (2013 thru 2020), Most Influential Women in Arizona Business (2014) and is a 2 time National Finalist for the Stevie Award which recognizes the work of women in business. Her past experience includes two years as the CEO of ASBA (the Arizona Small Business Association), service as a member of the Board of Trustees of the National Small Business Association in Washington D.C., President of the National Speakers Association/Arizona, Chair of the Board of Advisors to Parenting Arizona, the state's largest child abuse prevention organization, & much more.         AZBio:  Supporting Arizona's Life Science Industry for 19 Years (2003 – 2022) Learn more about Arizona's bioindustry: www.azbio.org | Facebook: AZBIO |Twitter: @AZBio @AZBioCEO We're part of a movement to create sustainable funding for life science innovation in Arizona. Learn more at www.AZAdvances.org  MOVING LIFE SCIENCE INNOVATIONS ALONG THE PATH FROM DISCOVERY TO DEVELOPMENT TO DELIVERY OUR VISION OF THE FUTURE: Arizona is a top-ten life science state. OUR MISSION: AZBio supports the needs of Arizona's growing life science ecosystem. The Arizona Bioindustry Association (AZBio) is a not-for-profit, 501(c)6 trade association supporting the growth of Arizona's life science sector. AZBio  Member Organizations in the fields of business, research and education, health care delivery, economic development, government, and other professions involved in the biosciences are the key drivers of the growth of Arizona's life science sector.  As the unified voice of our industry in Arizona, AZBio strives to make Arizona a place where bioscience organizations can grow and succeed.   AZBio works nationally and globally with the Advanced Medical Technology Association (AdvaMed), the Biotechnology Innovation Organization (BIO), the Medical Device Manufacturers Association (MDMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), and leading patient advocacy organizations. Through these relationships, AZBio has access to information, contacts, resources, cost saving programs, and the global bioscience and medtech community.   Arizona's bioscience industry is growing rapidly and reached nearly 30,000 jobs spanning 2,160 business establishments in 2018. Industry employment has grown by 15 percent since 2016—twice the growth rate of the nation—with each of the five major subsectors adding jobs during the period. Arizona's universities conducted nearly $580 million in R&D activities in bioscience-related fields in 2018, fueled in part by steadily increasing NIH awards to Arizona institutions since 2016. Venture capital investments in Arizona bioscience companies increased in 2019, and during the 2016-19 period totaled $349 million. Arizona inventors have been awarded 2,178 bioscience-related patents since 2016, among the second quintile of states in patent activity.   Notes:   Seg 1   Biotech and life sciences industry in Arizona, has 3000 businesses and 36,000 employees. The economic impact in 2021 was $38.5 billion. AZ Bio would like to double, so by 2033, the impact would be $78 billion.   Examples of biotech companies in Arizona are Medtronic that makes medical devices, WL Gore, material sciences. Other companies in diagnostics, there are Sonoran Quest which does testing. This also Castle Bio Sciences, deals in cancer treatment. Some medicine companies are Bristol, Myers, and Calvari who deals in cancer drugs. Calvari is the bio science company of the year in 2024.   AZ Bio Science Week started in 2017. AZ Bio week starts Oct. 13 (2025) and has events daily from Monday to Friday.     Example of one of the many companies involved with AZ Bio week:   CND Life Sciences - CND's Syn-One Test® offers physicians and patients an accurate, convenient, evidence-based tool to help diagnose a synucleinopathy. And our mission has just begun.   NIH - National Institute of Health gives grants or funding to universities, hospitals and even companies for medical research.   Takes time to build a medical device type product, a few years to decades.   Government is an important partner, that provides financial support. Examples are Medicare research, workforce help, and tax breaks. Many organizations like this are publicly funded with government and university help.  $25 billion in funding over the last 20 years in Arizona in bio investment. Government funded $5 billion, that's from state and federal sales tax at a penny per. $112 million funding to universities in 2022. Combination of industry, government and philanthropy. Discovery phase - university helps develop the IP and research. Technology is spun out of the university to corporate development by companies. The AZ Board of Regents owns the patents. They license the patents to companies. Then you have regulatory.  Distribution of a product. Successful products are profitable. They have a royalty that pays to the company, the university and the government. Example of this was the University of Florida created Gatorade in the 1970s and still gets royalties today. Process takes 10 to 15 years, with hundreds of people involved. Clinical trials of any type of drug takes years.   Creation of the Covid vaccine was an outlier, as many people had Covid at the time so it was very easy to put together big study groups       Seg 2   Examples of newer companies in biotech field –   Neo clinical stage company dealing in heart health with aortic artery for the abdomen.   Another new company is prim dealing in MCT deficiency, compound growth and they are in clinical and testing stages.   Drugs get tested through computer models, and then on animals. Always have to worry about safety and ethics. FDA has very strict rules. You do not put people at risk, after monitor, during test and post monitoring. There's high-level quality control.       AZ Bio has members that are in the bioscience industry with current companies   AZ Advances is about bio startups in early stage companies It's a 501 C nonprofit charity that is funding, internships, and education   Patient is not only the client, but the purpose for why biotech companies exist     Neuralink Corp. is an American neurotechnology company that has developed as of 2024 implantable brain–computer interfaces. It was founded by Elon Musk and a team of eight scientists and engineers. Neuralink was launched in 2016 and first publicly reported in March 2017.   Neuralink's first human patient, Noland Arbaugh, is an Arizona native who received his implant in January 2024 at the Barrow Neurological Institute in Phoenix. He will appear at Arizona Bioscience Week 2025     https://www.azbio.org/azbw2025     Events Summary:   Monday - Women in Biotech Leading Women: Biotech & Beyond Join us for an evening of conversation and connections with our community's leading women as we kick off Arizona Bioscience Week in style!   Tuesday - Fundraising Fundraising Strategies for Life Science Startups  A compelling narrative is crucial when you are fundraising and communicating with life science investors.  This Life Science Nation (LSN) Global Fundraising Bootcamp covers topics related to executing a successful fundraise for your startup.      Wednesday – AZ Bio awards, philanthropy, entertainment, and AZ Advances The 21st Annual AZBio Awards & AZAdvances After Party Celebrate with the Educators, Researchers, and Organizations that are making life better for people in Arizona and around the world.  Join us at the Phoenix Convention Center as we honor the 2024 AZBio Award Winners. Hundreds of health innovators and business leaders will be celebrating at the 20th Annual AZBio Awards.   Thursday -  AZAdvances   AZ Advances Health Innovation Summit This exclusive event will bring together health innovation leaders to share how are moving Arizona forward as we make life better for the people we serve.   AZ Advances: Arizonans are advancing life changing and life saving innovations along the path from discovery to development to delivery. AZAdvances is developing the funding that will help advance health innovations in Arizona today and for generations to come.  Charitable donations to the AZAdvances fund at the Opportunity Through Entrepreneurship Foundation, an Arizona based 501c3 public charity, are a way to support the creation of tomorrow's medical innovations.    Friday - Voice of the Patient Patients are the reason we do what we do.  Join the conversation on life science innovation from the patient perspective.        Seg. 3 Best of AZ Bio clips:   AZ Bio & Life Sciences Innovation w/ Joan Koerber-Walker - BRT S04 EP10 (172) 3-5-2023   Guest: Joan Koerber-Walker President and CEO, AZBio - Arizona Bioindustry Association, Inc. Chairman, Opportunity Through Entrepreneurship Foundation   Full Show: HERE     Guest: Stan Miele President & CBO Aqualung Therapeutics Corp LKIN: HERE www.aqualungtherapeutics.com   Stan Miele Bio: A recognized global executive with success in sales, marketing and P&L leadership in the pharmaceutical/medical device and biotech industries. Mr. Miele was formally the Chief Commercial Officer at bioLytical Laboratories and Sucampo Pharmaceuticals Inc.  He was also President of Sucampo Pharma Americas for 6 years.   He was instrumental on some key licensing agreements for Sucampo, inclusive of the agreement with Abbott Japan, and also Takeda Pharmaceuticals (now Shire).  He is actively part of the team ensuring proper execution of clinical development, manufacturing, licensing, capital funding, alliances, and ensuring Aqualung meets all critical milestones.  He will be helping the company move toward accelerating the pipeline/platform technology and moving eNamptor™ toward commercialization.   Aqualung Therapeutics  Aqualung Therapeutics (ALT) is developing multi-pronged strategies to address the development of severe lung inflammation which is essential to the severity and outcomes of acute and chronic lung disorders such as acute lung injury, ventilator-induced lung injury (VILI), idiopathic pulmonary fibrosis, and pulmonary hypertension. Effective FDA-approved drugs are either currently unavailable or extraordinarily modest in their ability to modify disease progression. No drug is currently available that is preventive or curative. Aqualung's strategies, which include deployment of a human monoclonal antibody which targets a novel inflammatory mediator (nicotinamide phosphoribosyltransferase or NAMPT) will address the unmet need for novel, effective therapies for VILI, IPF, and pulmonary hypertension.   Full Show: HERE       Seg. 4 – Clips from:  Preventing Cancer with a Vaccine w/ Stephen Johnston of Calviri  - BRT S04 EP17 (179) 4-23-2023   Guest: Stephen Johnston Founding CEO, Calviri Inc.  LKIN: HERE https://calviri.com/   Bio: Chief Executive Officer & Chairman of the Board Stephen Albert Johnston is the inventor of the Calviri's central technologies. In addition to Calviri, he has been a founder of Eliance, Inc. (Macrogenics), Synbody Biotechnology and HealthTell, Inc. He is Director of the Arizona State University Biodesign Institute's Center for Innovations in Medicine and Professor in the School of Life Sciences. He has published almost 200 peer-reviewed papers and holds 45 patents. Prior to his appointment at ASU he was Professor and Director of the Center for Biomedical Inventions at UT-Southwestern Medical Center and Professor of Biology and Biomedical Engineering at Duke University. He is a member of the National Academy of Inventors. Dr. Johnston received his B.S. and Ph.D. degrees from the University of Wisconsin.     Calviri Inc.  We are determined to offer humanity a better life, free from cancer. While our goal is hugely ambitious, we are intensely driven to rid the planet of worry from cancer. Calviri's mission is to provide affordable products worldwide that will end deaths from cancer. We are a fully integrated healthcare company developing a broad spectrum of vaccines and companion diagnostics that prevent and treat cancer for those either at risk or diagnosed. We focus on using frameshift neoantigens derived from errors in RNA processing to provide pioneering products against cancer. The company is a spin out of the Biodesign Institute, Arizona State University, located in Phoenix, AZ. We have the largest dog vaccine trial in the world underway at three premier veterinary universities. The five-year trial will assess the performance of a preventative cancer vaccine.   Full Show: HERE       ReFlow to Help Treat Hydrocephalus w/ Elsa Abruzzo & Mark Geiger of Anuncia Medical - BRT S04 EP23 (186) 6-11-2023     Guest: Elsa Chi Abruzzo RAC, FRAPS – President Elsa Chi Abruzzo is a medical device executive, entrepreneur, and a founding member of Anuncia, Inc., Alcyone Therapeutics, Arthromeda, Inc. and Cygnus Regulatory. Elsa has a 30+ year successful product development, operations, regulatory, quality, and clinical track record in med tech Industries. Her experience includes leadership positions at Baxter, Cordis JNJ, CryoLife, Percutaneous Valve Technologies, AtriCure, InnerPulse, Merlin MD, Sapheon, and PTS Diagnostics. Elsa earned a BS in engineering from the University of Miami in Coral Gables, FL and is regulatory affairs certified and a Regulatory Affairs Professional Society Fellow, recognized for her leadership in Regulatory and Quality by MDDI.   https://anunciamedical.com/the-anuncia-story/#team https://www.linkedin.com/in/elsachiabruzzo/   https://anunciamedical.com/ About Anuncia Conceptualized in 2014 in collaboration with Boston Children's Hospital and spun out of Alcyone Therapeutics in 2018, Anuncia's patented portfolio of technologies are intended to provide peace-of-mind through innovation. Our core ReFlow™ technology uses a simple finger depression of a soft silicone dome located under the patient's scalp to produce a noninvasive, one-way flush of the patient's own CSF directed toward the ReFlow™ catheter to restore or increase CSF flow through a non-flowing shunt and potentially avoid emergency surgery.  Learn More     The name Anuncia comes from Panthera Uncia, the species name of the snow leopard. These animals live in mountainous regions of Asia and have been called by the World Wildlife Foundation “Guardians of the Headwaters” as they roam the headwater areas of the western basins. The origin of the word hydrocephalus comes from the Greek hudrokephalon, from hudro ‘water'+ kephalē ‘head'. The snow leopard, or Guardian of the Headwaters, is a symbol of Anuncia's dedication to improve daily quality of life for the millions of underserved patients with hydrocephalus and other CSF disorders, as well as their families, who suffer from the clinical, economic, and emotional burden of repeat revision brain surgery due to VP shunt occlusions.      Full Show: HERE           Best of Biotech from AZ Bio & Life Sciences to Jellatech: HERE   Biotech Shows: HERE   AZ Tech Council Shows:  https://brt-show.libsyn.com/size/5/?search=az+tech+council *Includes Best of AZ Tech Council show from 2/12/2023      ‘Best Of' Topic: https://brt-show.libsyn.com/category/Best+of+BRT      Thanks for Listening. Please Subscribe to the BRT Podcast.     AZ Tech Roundtable 2.0 with Matt Battaglia The show where Entrepreneurs, Top Executives, Founders, and Investors come to share insights about the future of business.  AZ TRT 2.0 looks at the new trends in business, & how classic industries are evolving.  Common Topics Discussed: Startups, Founders, Funds & Venture Capital, Business, Entrepreneurship, Biotech, Blockchain / Crypto, Executive Comp, Investing, Stocks, Real Estate + Alternative Investments, and more…    AZ TRT Podcast Home Page: http://aztrtshow.com/ ‘Best Of' AZ TRT Podcast: Click Here Podcast on Google: Click Here Podcast on Spotify: Click Here                    More Info: https://www.economicknight.com/azpodcast/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/     Disclaimer: The views and opinions expressed in this program are those of the Hosts, Guests and Speakers, and do not necessarily reflect the views or positions of any entities they represent (or affiliates, members, managers, employees or partners), or any Station, Podcast Platform, Website or Social Media that this show may air on. All information provided is for educational and entertainment purposes. Nothing said on this program should be considered advice or recommendations in: business, legal, real estate, crypto, tax accounting, investment, etc. Always seek the advice of a professional in all business ventures, including but not limited to: investments, tax, loans, legal, accounting, real estate, crypto, contracts, sales, marketing, other business arrangements, etc.

Best of Biotech from AZ Bio & Life Sciences to Jellatech - BRT S04 EP26 (189) 7-2-2023   What We Learned This Week: AZ Bio mission to improve life sciences, & make AZ a Top 10 Bioscience state Aqualung Therapeutics is treating inflammation in the lungs, get people off ventilators & save lives Calviri is working on a Vaccine to PREVENT Cancer, currently largest animal clinical trial Anuncia Medical has a Re-Flow product to help drain fluid from the brain, treats Hydrocephalus Collagen 2.0 – Innovation to Gelatin & gummies     Seg. 1 – Clips from:  AZ Bio & Life Sciences Innovation w/ Joan Koerber-Walker - BRT S04 EP10 (172) 3-5-2023   Guest: Joan Koerber-Walker President and CEO, AZBio - Arizona Bioindustry Association, Inc. Chairman, Opportunity Through Entrepreneurship Foundation   LKIN: https://www.linkedin.com/in/joankoerberwalker  www.azbio.org Bio: As President and CEO of AZBio, Joan Koerber-Walker works on behalf of the Arizona Bioscience and Medical Technology Industry to support the growth of the industry, its members and our community on the local and national level. Ms. Koerber-Walker is also a life science investor and has served on the boards of numerous for-profit and non-profit organizations. In the life science industry, Ms. Koerber-Walker serves as as Arizona's representative to the State Medical Technology Alliance (SMTA), a consortium of state and regional trade associations representing their local medical technology companies which she chaired in 2015 and  represents Arizona as a member of the Council of State Bioscience Associations (CSBA) and the Coalition of State Bioscience Institutes (CSBI). Active in the entrepreneurial and investment communities, she also serves as Chairman of the Board of the Opportunity Through Entrepreneurship Foundation which provides entrepreneurial education, mentoring and support to at-risk members of the community, on the Board of Advisors to CellTrust, Inc. which provides secure communication technology to the healthcare industry, and as Chairman of CorePurpose, Inc. which she founded in 2002. Ms. Koerber-Walker has been recognized as Executive of the Year by the Arizona Society of Association Executives, as a “Most Admired Leader” by the Phoenix Business Journal (2015),  in the pages of AZ Business Leaders (2013 thru 2020), Most Influential Women in Arizona Business (2014) and is a 2 time National Finalist for the Stevie Award which recognizes the work of women in business. Her past experience includes two years as the CEO of ASBA (the Arizona Small Business Association), service as a member of the Board of Trustees of the National Small Business Association in Washington D.C., President of the National Speakers Association/Arizona, Chair of the Board of Advisors to Parenting Arizona, the state's largest child abuse prevention organization, & much more.     AZBio:  Supporting Arizona's Life Science Industry for 19 Years (2003 – 2022) Learn more about Arizona's bioindustry: www.azbio.org | Facebook: AZBIO |Twitter: @AZBio @AZBioCEO We're part of a movement to create sustainable funding for life science innovation in Arizona. Learn more at www.AZAdvances.org  MOVING LIFE SCIENCE INNOVATIONS ALONG THE PATH FROM DISCOVERY TO DEVELOPMENT TO DELIVERY OUR VISION OF THE FUTURE: Arizona is a top-ten life science state. OUR MISSION: AZBio supports the needs of Arizona's growing life science ecosystem. The Arizona Bioindustry Association (AZBio) is a not-for-profit, 501(c)6 trade association supporting the growth of Arizona's life science sector. AZBio  Member Organizations in the fields of business, research and education, health care delivery, economic development, government, and other professions involved in the biosciences are the key drivers of the growth of Arizona's life science sector.  As the unified voice of our industry in Arizona, AZBio strives to make Arizona a place where bioscience organizations can grow and succeed.   AZBio works nationally and globally with the Advanced Medical Technology Association (AdvaMed), the Biotechnology Innovation Organization (BIO), the Medical Device Manufacturers Association (MDMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), and leading patient advocacy organizations. Through these relationships, AZBio has access to information, contacts, resources, cost saving programs, and the global bioscience and medtech community.   Arizona's bioscience industry is growing rapidly and reached nearly 30,000 jobs spanning 2,160 business establishments in 2018. Industry employment has grown by 15 percent since 2016—twice the growth rate of the nation—with each of the five major subsectors adding jobs during the period. Arizona's universities conducted nearly $580 million in R&D activities in bioscience-related fields in 2018, fueled in part by steadily increasing NIH awards to Arizona institutions since 2016. Venture capital investments in Arizona bioscience companies increased in 2019, and during the 2016-19 period totaled $349 million. Arizona inventors have been awarded 2,178 bioscience-related patents since 2016, among the second quintile of states in patent activity.   Full Show: HERE     Guest: Stan Miele President & CBO Aqualung Therapeutics Corp LKIN: HERE www.aqualungtherapeutics.com   Stan Miele Bio: A recognized global executive with success in sales, marketing and P&L leadership in the pharmaceutical/medical device and biotech industries. Mr. Miele was formally the Chief Commercial Officer at bioLytical Laboratories and Sucampo Pharmaceuticals Inc.  He was also President of Sucampo Pharma Americas for 6 years.   He was instrumental on some key licensing agreements for Sucampo, inclusive of the agreement with Abbott Japan, and also Takeda Pharmaceuticals (now Shire).  He is actively part of the team ensuring proper execution of clinical development, manufacturing, licensing, capital funding, alliances, and ensuring Aqualung meets all critical milestones.  He will be helping the company move toward accelerating the pipeline/platform technology and moving eNamptor™ toward commercialization.   Aqualung Therapeutics  Aqualung Therapeutics (ALT) is developing multi-pronged strategies to address the development of severe lung inflammation which is essential to the severity and outcomes of acute and chronic lung disorders such as acute lung injury, ventilator-induced lung injury (VILI), idiopathic pulmonary fibrosis, and pulmonary hypertension. Effective FDA-approved drugs are either currently unavailable or extraordinarily modest in their ability to modify disease progression. No drug is currently available that is preventive or curative. Aqualung's strategies, which include deployment of a human monoclonal antibody which targets a novel inflammatory mediator (nicotinamide phosphoribosyltransferase or NAMPT) will address the unmet need for novel, effective therapies for VILI, IPF, and pulmonary hypertension.   Full Show: HERE       Seg. 2 – Clips from:  Preventing Cancer with a Vaccine w/ Stephen Johnston of Calviri  - BRT S04 EP17 (179) 4-23-2023   Guest: Stephen Johnston Founding CEO, Calviri Inc.  LKIN: HERE https://calviri.com/   Bio: Chief Executive Officer & Chairman of the Board Stephen Albert Johnston is the inventor of the Calviri's central technologies. In addition to Calviri, he has been a founder of Eliance, Inc. (Macrogenics), Synbody Biotechnology and HealthTell, Inc. He is Director of the Arizona State University Biodesign Institute's Center for Innovations in Medicine and Professor in the School of Life Sciences. He has published almost 200 peer-reviewed papers and holds 45 patents. Prior to his appointment at ASU he was Professor and Director of the Center for Biomedical Inventions at UT-Southwestern Medical Center and Professor of Biology and Biomedical Engineering at Duke University. He is a member of the National Academy of Inventors. Dr. Johnston received his B.S. and Ph.D. degrees from the University of Wisconsin.     Calviri Inc.  We are determined to offer humanity a better life, free from cancer. While our goal is hugely ambitious, we are intensely driven to rid the planet of worry from cancer. Calviri's mission is to provide affordable products worldwide that will end deaths from cancer. We are a fully integrated healthcare company developing a broad spectrum of vaccines and companion diagnostics that prevent and treat cancer for those either at risk or diagnosed. We focus on using frameshift neoantigens derived from errors in RNA processing to provide pioneering products against cancer. The company is a spin out of the Biodesign Institute, Arizona State University, located in Phoenix, AZ. We have the largest dog vaccine trial in the world underway at three premier veterinary universities. The five-year trial will assess the performance of a preventative cancer vaccine.   Full Show: HERE       ReFlow to Help Treat Hydrocephalus w/ Elsa Abruzzo & Mark Geiger of Anuncia Medical - BRT S04 EP23 (186) 6-11-2023     Guest: Elsa Chi Abruzzo RAC, FRAPS – President Elsa Chi Abruzzo is a medical device executive, entrepreneur, and a founding member of Anuncia, Inc., Alcyone Therapeutics, Arthromeda, Inc. and Cygnus Regulatory. Elsa has a 30+ year successful product development, operations, regulatory, quality, and clinical track record in med tech Industries. Her experience includes leadership positions at Baxter, Cordis JNJ, CryoLife, Percutaneous Valve Technologies, AtriCure, InnerPulse, Merlin MD, Sapheon, and PTS Diagnostics. Elsa earned a BS in engineering from the University of Miami in Coral Gables, FL and is regulatory affairs certified and a Regulatory Affairs Professional Society Fellow, recognized for her leadership in Regulatory and Quality by MDDI.   https://anunciamedical.com/the-anuncia-story/#team https://www.linkedin.com/in/elsachiabruzzo/   https://anunciamedical.com/ About Anuncia Conceptualized in 2014 in collaboration with Boston Children's Hospital and spun out of Alcyone Therapeutics in 2018, Anuncia's patented portfolio of technologies are intended to provide peace-of-mind through innovation. Our core ReFlow™ technology uses a simple finger depression of a soft silicone dome located under the patient's scalp to produce a noninvasive, one-way flush of the patient's own CSF directed toward the ReFlow™ catheter to restore or increase CSF flow through a non-flowing shunt and potentially avoid emergency surgery.  Learn More     The name Anuncia comes from Panthera Uncia, the species name of the snow leopard. These animals live in mountainous regions of Asia and have been called by the World Wildlife Foundation “Guardians of the Headwaters” as they roam the headwater areas of the western basins. The origin of the word hydrocephalus comes from the Greek hudrokephalon, from hudro ‘water'+ kephalē ‘head'. The snow leopard, or Guardian of the Headwaters, is a symbol of Anuncia's dedication to improve daily quality of life for the millions of underserved patients with hydrocephalus and other CSF disorders, as well as their families, who suffer from the clinical, economic, and emotional burden of repeat revision brain surgery due to VP shunt occlusions.      Full Show: HERE       2nd Half – Clip from:  Cell Based Collagen from Jellatech + BRT 2.2021 - Best of Tech 2021 BRT S02 EP13 (60) 03-28-2021   Guests: Stephanie Michelsen, Co-Founder / CEO Jellatech https://www.jellatech.com/   Stephanie Michelsen, founder and CEO of Jellatech, aims to use biotechnology to synthesize animal proteins - without killing the animals. This includes collagen and gelatin produced from animal cell lines and cultured in giant bioreactors to be used in food, pharma and cosmetic applications. Jellatech has raised $2.1 million. The Raleigh-based startup CEO lauded, lands on Forbes 30 under 30 https://www.forbes.com/profile/stephanie-michelsen/?sh=1a4e74ed778c   Jellatech is a developer of cutting-edge technologies to produce high quality, pure, animal-free collagen and gelatin. Founded by a group of innovators, dreamers, entrepreneurs and scientists, Jellatech is on a mission to eliminate animals from the food system, making better ingredient products - starting with collagen and gelatin. Collagen is a by-product of the meat industry (protein in the body). You may be familiar with collagen from seeing it in skin serums, or with its derivative, gelatin, in gummy bears - but it's likely around you much more than you realize. This ingredient is used in a number of applications such as for food texturizers, vaccine stabilizers, pill capsules, the clarification of wine and beer, and many more.  Today, the only way to source native, functional collagen is to extract it from animals. This is what they are changing at Jellatech. Jellatech makes functional, native collagen - without animals. Cellular agriculture enables one to produce a more sustainable, smarter high quality collagen that breaks the cycle of relying on an inefficient and unethical supply chain of live animals.   Full Show: HERE       AZ Tech Council Shows:  https://brt-show.libsyn.com/size/5/?search=az+tech+council *Includes Best of AZ Tech Council show from 2/12/2023   Tech Topic: https://brt-show.libsyn.com/category/Tech-Startup-VC-Cybersecurity-Energy-Science  Best of Tech: https://brt-show.libsyn.com/size/5/?search=best+of+tech     ‘Best Of' Topic: https://brt-show.libsyn.com/category/Best+of+BRT      Thanks for Listening. Please Subscribe to the BRT Podcast.     Business Roundtable with Matt Battaglia The show where Entrepreneurs, High Level Executives, Business Owners, and Investors come to share insight and ideas about the future of business. BRT 2.0 looks at the new trends in business, and how classic industries are evolving.  Common Topics Discussed: Business, Entrepreneurship, Investing, Stocks, Cannabis, Tech, Blockchain / Crypto, Real Estate, Legal, Sales, Charity, and more…  BRT Podcast Home Page: https://brt-show.libsyn.com/ ‘Best Of' BRT Podcast: Click Here BRT Podcast on Google: Click Here BRT Podcast on Spotify: Click Here                    More Info: https://www.economicknight.com/podcast-brt-home/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/   Disclaimer: The views and opinions expressed in this program are those of the Hosts, Guests and Speakers, and do not necessarily reflect the views or positions of any entities they represent (or affiliates, members, managers, employees or partners), or any Station, Podcast Platform, Website or Social Media that this show may air on. All information provided is for educational and entertainment purposes. Nothing said on this program should be considered advice or recommendations in: business, legal, real estate, crypto, tax accounting, investment, etc. Always seek the advice of a professional in all business ventures, including but not limited to: investments, tax, loans, legal, accounting, real estate, crypto, contracts, sales, marketing, other business arrangements, etc.    

Preventing Cancer with a Vaccine w/ Stephen Johnston of Calviri   - BRT S04 EP17 (179) 4-23-2023   Things We Learned This Week Calviri is working on a Vaccine to PREVENT Cancer, currently largest animal clinical trial Inflammation - starting points of bad cells Cancer - bad cells replicate Could Prevent other diseases & extend longevity of people's lives - ex.- help w/ dementia Tumors make bad proteins Calviri vaccine works on RNA (proteins) kills tumor, & arms immune system       Guest: Stephen Johnston Founding CEO, Calviri Inc. LKIN: HERE https://calviri.com/    Bio: Chief Executive Officer & Chairman of the Board Stephen Albert Johnston is the inventor of the Calviri's central technologies. In addition to Calviri, he has been a founder of Eliance, Inc. (Macrogenics), Synbody Biotechnology and HealthTell, Inc. He is Director of the Arizona State University Biodesign Institute's Center for Innovations in Medicine and Professor in the School of Life Sciences. He has published almost 200 peer-reviewed papers and holds 45 patents. Prior to his appointment at ASU he was Professor and Director of the Center for Biomedical Inventions at UT-Southwestern Medical Center and Professor of Biology and Biomedical Engineering at Duke University. He is a member of the National Academy of Inventors. Dr. Johnston received his B.S. and Ph.D. degrees from the University of Wisconsin.    Calviri Inc. We are determined to offer humanity a better life, free from cancer. While our goal is hugely ambitious, we are intensely driven to rid the planet of worry from cancer. Calviri's mission is to provide affordable products worldwide that will end deaths from cancer. We are a fully integrated healthcare company developing a broad spectrum of vaccines and companion diagnostics that prevent and treat cancer for those either at risk or diagnosed. We focus on using frameshift neoantigens derived from errors in RNA processing to provide pioneering products against cancer. The company is a spin out of the Biodesign Institute, Arizona State University, located in Phoenix, AZ. We have the largest dog vaccine trial in the world underway at three premier veterinary universities. The five-year trial will assess the performance of a preventative cancer vaccine.    Notes:  Seg. 1   Calviri working to develop a vaccine to prevent cancer, not cure, but prevent. You would take the vaccine like any other vaccine. Currently testing a largest clinical trial of 800 dogs. They are in year 3 of a 5 year trial.  Dr. Johnston has been working on this for 15 years thus far.  There will be 2 phases, with Phase 1 being animal testing to create a dog vaccine. This is a $3 – 5 billion industry. Next year, Calviri wants to launch with FDA approval.  Phase 2 is Human clinical trials. These will be Therapeutic trials, working on treating cancer.  The Best Part of Calviri's research and vaccine is it could prevent other diseases also. In turn give more longevity of life for people, and maybe cure dementia. Inflammation is the starting point. Defined: localized physical condition in which part of the body becomes reddened, swollen, hot, and often painful, especially as a reaction to injury or infection.  In a normal inflammatory response, immune cells produce chemicals that can kill a pathogen. These chemicals, known as reactive oxygen species, can also damage the DNA of normal cells, which increases the risk of mutations that could lead to cancer. Bad cells or zombie cells are put out. Bad stuff, don't die, cause inflammation to other cells Cancer is when bad cells replicate uncontrollably. Sometimes this orderly process breaks down, and abnormal or damaged cells grow and multiply when they shouldn't. These cells may form tumors, which are lumps of tissue. Tumors can be cancerous or not cancerous (benign).  It can also cause bone dysfunction. Tumor is a normal cell, not part of a community like infection Body is made up of tissues and cells (community or tightly packed group of cells). All cells experience changes with aging. They become larger and are less able to divide and multiply. Among other changes, there is an increase in pigments and fatty substances inside the cell (lipids). Many cells lose their ability to function, or they begin to function abnormally.  A person's Immune system fixes the community of cells & wipes out ‘rogue' tumors.   Seg. 2  Stephen Johnston's background,  trained in science, and also an inventor with a degree in bio chemistry. Was working at UT Southwest Medical Center in Dallas, TX. Started working at ASU about 15 years ago to develop what would become the Calviri research. ASU supporting the Calviri patent.  Started Calviri Inc. circa 2018. It was a spun out patent & I.P. to Calviri, with an exclusive license to Calviri. ASU owns no equity which is unusual. Gets % of profits – did not invest Venture Capital or VC wants equity in any deal they invest in. They also do not want any Universities having ownership as it complicates a deal. Calviri Board has 6 members, with a few members also providing funding, this is an  uncommon setup. Calviri Stock in all common One of the board members is the former CEO of Humana  $2 Bill – Open Philanthropy is a philanthropic funder. Our mission is to help others as much as we can with the resources available to us. Our main funders are Cari Tuna and Dustin Moskovitz, a co-founder of Facebook and Asana. This organization is providing funding for health companies.  High risk – 2019 - $6 5 mil  Calviri 4/2023 Worldwide MKT – affordable   Seg. 3  Clinical trial phase, do hundreds of trials Common treatment for a person who has cancer, create a Personalized cancer vaccine with an estimated cost of $100k DNA sequencing is done, and that treatment is for that person only Calviri mission is to create an off the shelf & affordable product Stepping stone in medicine development, goes from therapeutic to prevention Moderna, one of the big phrama companies that made the Covid vaccine  MRNA Vaccine Survey blood w/ stage 1 or 3 cancer, search for commonalities Intel chip system being used in bio chemistry machines. Intel says its processors are behind efforts to find new breakthroughs in life sciences research and healthcare in a number of countries. It took 10 years of work to test blood DNA transcription produces a single-stranded RNA molecule that is complementary to one strand of DNA. In the first step, the information in DNA is transferred to a messenger RNA (mRNA) molecule by way of a process called transcription. Processing mistakes at the RNA level  Reduced to pieces to become  Proteins – tumor makes bad protein, which looks like a inflection Takes pieces of bad protein & make a vaccine, then Inject the vaccine & kill the tumor Teach your body, arm the immune system before foreign particle are created Pre-emptively give vaccine before there is any cancer cells     Seg. 4   The common theme of Calviri is simplicity. There are simple ways to do x.   Everyone said it's complicated to treat cancer. There are 200 types of cancer. Calviri is working to have a big impact, plus make their vaccine simple & affordable. They believe the logical solution is vaccines.   They have shown to prevent cancer in their trials with dogs.   Trial –   Find the common traits. As the expression goes: The light is better under lamppost.   Common research is done on DNA to learn about Cancer. A person with Cancer has their DNA mapped out and the treatment created is for them only.   The harder method is to look at RNA.   Found parts in tumor – foreign   1 preventive vaccine working with ‘common' traits in RNA, there are 40 component pieces of proteins. There hundreds (100s) of uncommon traits   Immune system has sensor cells Immune system response, it will identify foreign cells & destroy them   Auto ‘self' immune disease - attacks all cells Good cells – working too well, and attacking non bad cells    When we age, it is common for the immune system to break down. This make people more prone to cancer, or other diseases.   Anti-Aging is a topic getting attention and funding. Jeff Bezos has invested in Altos Labs. Altos is pursuing biological reprogramming technology, a way to rejuvenate cells in the lab that some scientists think could be extended to revitalize entire animal bodies, ultimately prolonging human life.       Thanks to Joan Kerber-Walker of Az Bio for the intro to Stan. AZ Bio & Life Sciences Innovation w/ Joan Koerber-Walker - BRT S04 EP10 (172) 3-5-2023   FULL Show w/ Joan of AZ Bio: Click HERE     AZ Tech Council Shows: HERE *Includes Best of AZ Tech Council show from 2/12/2023   Tech Topic: HERE Best of Tech: HERE    ‘Best Of' Topic: https://brt-show.libsyn.com/category/Best+of+BRT      Thanks for Listening. Please Subscribe to the BRT Podcast.     Business Roundtable with Matt Battaglia The show where Entrepreneurs, High Level Executives, Business Owners, and Investors come to share insight and ideas about the future of business. BRT 2.0 looks at the new trends in business, and how classic industries are evolving.  Common Topics Discussed: Business, Entrepreneurship, Investing, Stocks, Cannabis, Tech, Blockchain / Crypto, Real Estate, Legal, Sales, Charity, and more…  BRT Podcast Home Page: https://brt-show.libsyn.com/ ‘Best Of' BRT Podcast: Click Here BRT Podcast on Google: Click Here BRT Podcast on Spotify: Click Here                    More Info: https://www.economicknight.com/podcast-brt-home/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/   Disclaimer: The views and opinions expressed in this program are those of the Hosts, Guests and Speakers, and do not necessarily reflect the views or positions of any entities they represent (or affiliates, members, managers, employees or partners), or any Station, Podcast Platform, Website or Social Media that this show may air on. All information provided is for educational and entertainment purposes. Nothing said on this program should be considered advice or recommendations in: business, legal, real estate, crypto, tax accounting, investment, etc. Always seek the advice of a professional in all business ventures, including but not limited to: investments, tax, loans, legal, accounting, real estate, crypto, contracts, sales, marketing, other business arrangements, etc.    

Did you know that the herbicide glyphosate can cross the blood-brain barrier, resulting in an increase of neuro-inflammation? Join Food Sleuth Radio host and Registered Dietitian, Melinda Hemmelgarn, for her interview with Ramon Velazquez, Ph.D., Assistant Professor in the School of Life Sciences, and Neurodegenerative Disease Research Center at the Biodesign Institute, Arizona State University. Velaquez discusses his new published research on the effects of glyphosate on the brains of mice, showing that it may increase the risk of neurodegenerative disorders. “Glyphosate infiltrates the brain and increases pro-inflammatory cytokine TNFα: implications for neurodegenerative disorders.” https://pubmed.ncbi.nlm.nih.gov/35897073/ He also discusses the role of choline in cognitive health and how it may reduce the risk of Alzheimer's Disease.Related website:   https://velazquezlab-asu.github.io/index.html 

We welcome YOU back to America's leading higher education podcast, The EdUp Experience! It's YOUR time to #EdUp In this episode, President Series #150, YOUR guest is Dr. Michael Crow, President of Arizona State University (ASU), YOUR guest cohost is Ryan Stowers, Executive Director at The Charles Koch Foundation, YOUR host is Dr. Joe Sallustio, & YOUR sponsor is Google! Want to know how to innovate to personalize learning at scale? Listen in to find out! YOU can not miss this episode! Michael M. Crow is an educator, knowledge enterprise architect, science & technology policy scholar, & higher education leader. He became the 16th president of Arizona State University in July 2002 & has spearheaded ASU's rapid & groundbreaking transformative evolution into one of America's best public metropolitan research universities. As a model “New American University,” ASU simultaneously demonstrates comprehensive excellence, inclusivity representative of the ethnic & socioeconomic diversity of the United States, & consequential societal impact. Under his leadership, ASU has established 25 new transdisciplinary schools, including the School of Earth & Space Exploration, the School for the Future of Innovation in Society, & the School of Human Evolution & Social Change, & launched trailblazing multidisciplinary initiatives including the Biodesign Institute, the Julie Ann Wrigley Global Futures Laboratory, & important initiatives in the humanities & social sciences. Thank YOU so much for tuning in. Join us on the next episode for YOUR time to EdUp! Connect with YOUR EdUp Team - Elvin Freytes & Dr. Joe Sallustio ● Join YOUR EdUp community at The EdUp Experience! We make education YOUR business! --- Send in a voice message: https://anchor.fm/edup/message

Dr. Stephen Johnston, Ph.D. (https://biodesign.asu.edu/stephen-johnston) is the Director for the Center for Innovations in Medicine, a Professor in the School of Life Sciences, and Director of the Biological Design Graduate Program at The Biodesign Institute at Arizona State University. Dr Johnston is also Founding CEO and Chairman of the Board Of Directors of Calviri (https://calviri.com/). The Center for Innovations in Medicine and Dr. Johnston's current work focuses on innovative solutions to fundamental problems in bio-medicine, and their organization brings together a unique group of interdisciplinary scientists to identify, analyze, and come up with inventive solutions for significant un-met medical needs. Current major translational sciences and technology development projects of Dr. Johnston include 1) Cancer Eradication: with a focus on developing a universal, preventative cancer vaccine, and 2) Health Futures: with an aim of producing a diagnostic system that allows continuous monitoring of the health status of healthy people - helping in the revolution to pre-symptomatic medicine. Dr. Johnston has broad experience in basic science, including cloning the Gal4 gene, showing that proteins have separable functional domains, and discovering the ATPases Associated proteins and their role in transcription. He was also co-inventor/innovator of pathogen derived resistance, organelle transformation, the gene gun, genetic immunization, Tobacco Etch Virus protease system, expression library immunization, linear expression elements, synbodies and immunosignaturing. Dr. Johnston is author of over 150 journal articles, has over 20 patents, and has garnered approximately $85M in grant support including large programs from DARPA, NIAID and NHLBI. Dr. Johnston has a B.S. in Molecular Biology and Ph.D. in Genetics and Plant Genetics/Plant Breeding, from the University of Wisconsin-Madison, and did Postdoctoral work in Biochemistry at Penn State University Medical Center.

The executive director of ASU's Biodesign Institute urges caution around holiday gatherings as COVID-19 cases continue to increase. Plus, why one Arizona congressman sees the Build Back Better Act as a way to lower prescription drug prices, and a new report reveals how low Black homeownership is in Arizona. ---Host: Emma VandenEinde Producer: Michael Baribault, Emma VandenEindeContributors: Lauren Quinlan, Samantha Byrd and Sara Edwards

Can breast cancer be found with a blood test? What role do genes and proteins play in developing cancer? What, exactly, are personalized diagnostics? We spoke with BCRF investigator Dr. Joshua LaBaer to answer these questions and more. Dr. LaBaer is one of the country's foremost investigators in personalized medicine. He serves as executive director of the Biodesign Institute, director of the Biodesign Virginia G. Piper Center for Personalized Diagnostics, and the Dalton Endowed Chair of Cancer Research at Arizona State University. Dr. LaBaer's research involves discovering and validating biomarkers to detect cancer and other diseases early.

Today we're back with our COVID-19 Roundtable. It's almost Fall, and much like the temperatures in Arizona, COVID-19 numbers are starting to stabilize, but they're still too high for comfort.  It's been one month since we last spoke with our COVID-19 panelists, and in that time, we've experienced what seems to be a turn for the better. But will these improvements last? What effect will recent local and federal policies have on transmission? To discuss those topics and much more, we're speaking with Dr. Kara Geren of Valleywise Health, Dr. Joshua LaBaer from ASU's Biodesign Institute and Will Humble from the Arizona Public Health Association.

Today, after more than a two-month hiatus, we're back with our COVID-19 Roundtable. And my how things have changed in the past two months. You know it from your daily experiences, you've heard it from our guests, the COVID-19 rollercoaster continues. We're well into our third wave of COVID-19 infections, this time largely due to the Delta variant, and hospital COVID-19 metrics are following suit. The CDC has recommended that all people, vaccinated and unvaccinated, wear a mask indoors in public when in an area of substantial or high transmission (which is the status of nearly every county in the United States). Our kids, most of whom are still too young to receive a COVID-19 vaccine, are headed back to in-person learning inside of schools that are battling new laws which remove schools' abilities to require masks and vaccinations. Without question, this pandemic is not over. But there's always hope. The latest research shows that vaccines are safe and effective. They're good at slowing the spread and great at preventing sickness and death. Our first guest serves our eyes and ears on the medical frontlines. She's an emergency medicine physician at Valleywise Health, Dr. Kara Geren. Next, he's the reason that many of us were able to spit into tubes and avoid those annoying nasal swabs when getting tested for COVID-19, Executive Director of ASU's Biodesign Institute, Dr. Joshua LaBaer.  And finally, the common thread that stretches all the way back to the very first CV19 Roundtable in March of 2020, he's the Executive Director of the Arizona Public Health Association, Will Humble. Here is what we know as of August 16, 2021.

Dr. Grant McFadden is trying to find out if a virus fatal only to rabbits might also destroy cancer cells. He became interested in the myxoma virus in grad school. The virus was first released in Australia in the 1950s to try to control a massive rabbit population . Since then, Grant has turned his interest into a lifelong pursuit of understanding viruses. Now, as a virologist and researcher at ASU's Biodesign Institute, he's altering viruses and learning how these viruses could treat cancer. In this episode, Dr. McFadden tells Hamid about his research and discusses the importance of the FDA and the development and safety of the Covid-19 vaccines.

"A tumor grows out of what's, at default, a state of cooperation," says researcher Carlo Maley. His research interest centers on the intersection of cancer and evolution and ways to use that understanding to treat cancer. He shares fascinating studies and theories with listeners, exploring How growing a tumor in vitro into a spheroid allows researchers to study it as an organism, How cancer cells transitioning from epithelial to mesenchymal tissue enables mobility, What the "Big Bang" hypothesis means in cancer research, and Why understanding the low cancer rate in whales might help our own treatment. Carlo Maley is an associate professor with the Biodesign Institute in the School of Life Sciences at Arizona State University and is the director of the Arizona Cancer and Evolution Center. He specializes in cancer, evolution, and computational biology. He explains that cancer and evolution intersect on two different levels. First, within our bodies, cells are evolving and competing, mutating and surviving or failing. These processes can lead to the beginnings of cancer. Second, when doctors treat cancer with methods like chemotherapy, selective pressures again determine evolutionary forces, leading to resistance. Professor Maley explores both of these levels in imaginative detail, explaining for example how bone marrow cancer growth and lung cancer may have different pressures and mechanism to progress through natural selection and competition. It's this competition of cells that creates phenomena such as removing a tumor leading to increased metastases. He explains that, in "many of these mutations. . .  that affect the biology of a cell, actually, are going to be advantageous for the cell, but ultimately bad for the body." Yet, cancer cells are able to coopt cellular machinery that leads to cooperation. He touches on numerous puzzles, including the role of bacteria and microbiomes in some cancers, and shares some exciting research into adaptive therapies. Listen in for an enlightening and hopeful view into cutting-edge cancer research. Episode also available on Apple Podcasts: apple.co/30PvU9C

Dr. Joshua LaBaer, Executive Director of the Biodesign Institute at ASU, called in to discuss ASU's new COVID-19 model. See omnystudio.com/listener for privacy information.

Gaydos and Chad talk to Dr. LaBaer about COVID in Arizona. Find out if another surge is coming, where the spread is happening the most and why you should get vaccinated.  See omnystudio.com/listener for privacy information.

Have you ever wondered when we will finally understand the science we need to beat cancer?    Well today’s guest on the podcast, Dr. Stephen Johnston, has some fascinating research to share with us about preventing cancer in dogs, and hopefully humans.    Stephen Johnston is the director for the Center for Innovations in Medicine (CIM), a Professor in the School of Life Sciences, and Director of the Biological Design Graduate Program at The Biodesign Institute at Arizona State University. He has authored over 150 journal articles, has over 20 patents, and even developed a gene gun which delivers the melanoma vaccine.   Today he’s talking to us about one of his main projects, cancer eradication and the development of  a universal preventative cancer vaccine. He’s bringing us up to date on his Vaccination Against Canine Cancer Study and how you might be able to help.    If you want to find out how you could be part of changing the future of cancer prevention, make sure you tune in to this episode.    Show notes available at www.caninecanceracademy.com/podcast-ep-6 Don’t forget to say hello on Instagram @thecaninecaneracademy and on Facebook Canine Cancer Academy

Reliable and fast testing are needed all over the US to confront the spread of COVID-19. We talk to Dr. Joshua LaBaer about his lab’s robotic systems—and how to use and expand testing most effectively. When the Covid-19 pandemic hit, LaBaer, executive director of ASU’s Biodesign Institute, transformed one of his labs into a high-volume coronavirus testing lab. This lab was originally developed to do high-volume testing for radiation in case of nuclear disaster. We talk about how the lab works, how to best do testing and contacting tracing, and how to incorporate both of these into strategic plans to reopen society.

Reliable and fast testing are needed all over the US to confront the spread of COVID-19. We talk to Dr. Joshua LaBaer about his lab’s robotic systems—and how to use and expand testing most effectively. When the Covid-19 pandemic hit, LaBaer, executive director of ASU’s Biodesign Institute, transformed one of his labs into a high-volume coronavirus testing lab. This lab was originally developed to do high-volume testing for radiation in case of nuclear disaster. We talk about how the lab works, how to best do testing and contacting tracing, and how to incorporate both of these into strategic plans to reopen society.

Alzheimer's Disease can be treated with a method so easy as diet, says Scientist. In a new study, researchers at the Biodesign Institute discover a safe and simple cure for one of the most devastating and perplexing afflictions: Alzheimer’s Disease (AD). More at: https://www.neuroscientia.com/2019/01/essential-nutrients-may-help-combat-Alzheimers.html

Founding Director of the Biodesign Institute at Arizona State and former BTI President Charles Arntzen discusses risk-taking in science research and his role in human vaccines.

Rolf Halden studies the impact of dangerous chemicals on human health. Halden, director of the Center for Environmental Health Engineering at ASU’s Biodesign Institute, monitors sewage in hundreds of locations around the U.S. to measure the health of our cities and their people.

Rolf Halden studies the impact of dangerous chemicals on human health. Halden, director of the Center for Environmental Health Engineering at ASU’s Biodesign Institute, monitors sewage in hundreds of locations around the U.S. to measure the health of our cities and their people.

In partnership with the Research Advocacy Network, CSC presents a show on the role of tissue sampling in the cancer continuum. Did you know that tissue can be donated at any point in one's life, as well as from those living with cancer, and their family members? Learn more with Dr. LaBaer, Director of the Virginia G. Piper Center for Personalized Diagnostics at the Biodesign Institute at Arizona State University and Kay Kays, a four-time pancreatic cancer survivor and patient advocate with Research Advocacy Network.

In partnership with the Research Advocacy Network, CSC presents a show on the role of tissue sampling in the cancer continuum. Did you know that tissue can be donated at any point in one's life, as well as from those living with cancer, and their family members? Learn more with Dr. LaBaer, Director of the Virginia G. Piper Center for Personalized Diagnostics at the Biodesign Institute at Arizona State University and Kay Kays, a four-time pancreatic cancer survivor and patient advocate with Research Advocacy Network.

Host: Steven Edelman, MD Guest: Jeffrey La Belle, PhD Many patients do not test blood glucose levels as often as they should, due to pain associated with the finger stick, as well as the need for an excess of testing paraphernalia. This week's guest discusses a potential non-invasive test on the horizon that would use tears to measure glucose levels. Dr. Jeffrey La Belle, biomedical engineering research professor in the School of Biological and Health Systems Engineering in Arizona State University's Ira A. Fulton Schools of Engineering and the Biodesign Institute, discusses promising new research in testing that may improve effectiveness and compliance with measuring blood glucose.

Guest: Jeffrey La Belle, PhD Host: Steven Edelman, MD Many patients do not test blood glucose levels as often as they should, due to pain associated with the finger stick, as well as the need for an excess of testing paraphernalia. This week's guest discusses a potential non-invasive test on the horizon that would use tears to measure glucose levels. Dr. Jeffrey La Belle, biomedical engineering research professor in the School of Biological and Health Systems Engineering in Arizona State University's Ira A. Fulton Schools of Engineering and the Biodesign Institute, discusses promising new research in testing that may improve effectiveness and compliance with measuring blood glucose.

Michael M. Crow became the 16th president of Arizona State University on July 1 2002. He is guiding the transformation of ASU into one of the nation s leading public metropolitan research universities. Since he took office ASU, a number of milestones have occurred, including the establishment of major interdisciplinary research initiatives such as the Biodesign Institute, the Global Institute for Sustainability and MacroTechnology. Also under Crow's direction ASU has initiated a dramatic research infrastructure expansion to create more than one million square feet of new research space and has announced naming gifts endowing the W. P. Carey School of Business the Ira A. Fulton School of Engineering and the Virginia G. Piper Center for Creative Writing. Prior to joining ASU, Crow served as executive vice provost of Columbia University where he also was professor of science and technology policy in the School of International and Public Affairs.

Bruce Rittmann, the Director of the Center for Environmental Biotechnology at the Biodesign Institute of Arizona State, focuses his efforts on reclaiming contaminated water and producing renewable energy using microbes. He was elected to the National Academy of Engineering in 2004 and credited with pioneering development of biofilm fundamentals and contributing to their widespread use in the bioremediation of contaminated ecosystems. His research combines many disciplines of science, including engineering, microbiology, biochemistry, geochemistry and microbial ecology. Formerly with Northwestern University, Rittmann is also a leader in the development of the Membrane Biofilm Reactor, an approach that uses bacteria to destroy pollutants in water. The Membrane Biofilm Reactor is especially effective for removing perchlorate from drinking water, and it is being launched commercially. In this podcast, I talk with Dr. Rittmann about the biofilm reactor process, the electricity hiding in our wastewater, and how we may some day grow fuel on the roofs of buildings.

Bruce Rittmann, the Director of the Center for Environmental Biotechnology at the Biodesign Institute of Arizona State, focuses his efforts on reclaiming contaminated water and producing renewable energy using microbes. He was elected to the National Academy of Engineering in 2004 and credited with pioneering development of biofilm fundamentals and contributing to their widespread use in the bioremediation of contaminated ecosystems. His research combines many disciplines of science, including engineering, microbiology, biochemistry, geochemistry and microbial ecology. Formerly with Northwestern University, Rittmann is also a leader in the development of the Membrane Biofilm Reactor, an approach that uses bacteria to destroy pollutants in water. The Membrane Biofilm Reactor is especially effective for removing perchlorate from drinking water, and it is being launched commercially. In this podcast, I talk with Dr. Rittmann about the biofilm reactor process, the electricity hiding in our wastewater, and how we may some day grow fuel on the roofs of buildings.